CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer.

CATCH (Comprehensive Assessment of clinical feaTures and biomarkers to identify patients with advanced or metastatic breast Cancer for marker driven trials in Humans) is a prospective precision oncology program that uses genomics and transcriptomics to guide therapeutic decisions in the clinical management of metastatic breast cancer. Herein, we report our single-center experience and results on the basis of the first 200 enrolled patients of an ongoing trial. From June 2017 to March 2019, 200 patients who had either primary metastatic or progressive disease, with any number of previous treatment lines and at least one metastatic site accessible to biopsy, were enrolled. DNA and RNA from tumor tissue and corresponding blood-derived nontumor DNA were profiled using whole-genome and transcriptome sequencing. Identified actionable alterations were brought into clinical context in a multidisciplinary molecular tumor board (MTB) with the aim of prioritizing personalized treatment recommendations. Among the first 200 enrolled patients, 128 (64%) were discussed in the MTB, of which 64 (50%) were subsequently treated according to MTB recommendation. Of 53 evaluable patients, 21 (40%) achieved either stable disease (n = 13, 25%) or partial response (n = 8, 15%). Furthermore, 16 (30%) of those patients showed improvement in progression-free survival of at least 30% while on MTB-recommended treatment compared with the progression-free survival of the previous treatment line. The initial phase of this study demonstrates that precision oncology on the basis of whole-genome and RNA sequencing is feasible when applied in the clinical management of patients with metastatic breast cancer and provides clinical benefit to a substantial proportion of patients.

Informations de copyright

© 2021 by American Society of Clinical Oncology.

Déclaration de conflit d'intérêts

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Carlo FremdHonoraria: Roche, Pfizer, Celgene, AstraZeneca, Amgen Consulting or Advisory Role: Roche, Pfizer Travel, Accommodations, Expenses: Celgene, RocheLaura MichelHonoraria: AstraZeneca, Roche, Eisai, LillyDaniela RichterTravel, Accommodations, Expenses: IlluminaPeter HorakHonoraria: IpsenAlbrecht StenzingerConsulting or Advisory Role: AstraZeneca, Novartis, Bristol Myers Squibb, Bayer, Illumina, Thermo Fisher Scientific, Janssen, Lilly, Seattle Genetics, Takeda, AGCT Speakers' Bureau: Bristol Myers Squibb, AstraZeneca, MSD, Roche, Bayer, Illumina, Thermo Fisher Scientific, Novartis Research Funding: Chugai Pharma, Bristol Myers Squibb, BayerChristoph SpringfeldConsulting or Advisory Role: Celgene, Servier, Eisai, Roche, MSD, Bayer Travel, Accommodations, Expenses: Celgene, ServierKatharina SmetanayHonoraria: Celgene, Roche, Pfizer Travel, Accommodations, Expenses: CelgeneAthanasios MavratzasHonoraria: Roche, Eisai Europe, Pfizer Travel, Accommodations, Expenses: Roche, Eisai, PfizerFlorian SchuetzHonoraria: Roche, Pfizer, MSD Oncology, Amgen, AstraZeneca Consulting or Advisory Role: MSD OncologyStefan FröhlingHonoraria: PharmaMar, Roche, Lilly, Amgen Consulting or Advisory Role: Bayer, Illumina, Roche Research Funding: AstraZeneca, PharmaMar, Pfizer, Roche Travel, Accommodations, Expenses: PharmaMar, Roche, Lilly, AmgenHans-Peter SinnHonoraria: NanoString Technologies, Roche Pharma AG Research Funding: Roche Pharma AG Travel, Accommodations, Expenses: NanoString TechnologiesDirk JägerConsulting or Advisory Role: Roche/Genentech, Bristol Myers Squibb, BioNTech AG, AmgenAndreas SchneeweissHonoraria: Roche Pharma AG, Celgene, AstraZeneca, Pfizer, Novartis, MSD Oncology, Lilly, Tesaro Research Funding: Roche Pharma AG, Celgene, Abbvie, Molecular Partners Expert Testimony: Roche, AstraZeneca Travel, Accommodations, Expenses: Roche, Celgene No other potential conflicts of interest were reported.